Clinical trials

A phase I study of an innovative drug used in the treatment of patients with a new coronavirus infection (COVID-19) has been completed. The final report has been prepared.

CPD has developed a strategy for preclinical and clinical study of a new prolonged finished dosage form in order to further obtain a registration certificate.

CPD has received permission from the Ministry of Health of Russia and is starting to conduct the clinical part of the bioequivalence study of a drug used in the treatment of inflammatory and degenerative diseases of the musculoskeletal system, pain syndrome from the spine (lumbago, neuralgia, myalgia,...

The phase III study has been completed and the final report of the study on the evaluation of the efficacy and safety of the drug used in the treatment of attention deficit hyperactivity disorder (ADHD) has been prepared in children 6-12 years of age with different dosage regimens.

The SRV organized three studies of user testing of the text of the instructions for medical use (leaflet) of the medicinal product for medical use.

CPD employees have prepared a number of protocols and related documents for obtaining permission from the Ministry of Health of the Russian Federation to conduct bioequivalence studies of medicines.

CPD has received permission from the Ministry of Health of Russia to conduct bioequivalence studies of a series of drugs.

CPD employees have prepared a number of protocols and other documents necessary to obtain permission from the Ministry of Health of the Russian Federation to conduct drug research.

CPD has started a phase I clinical trial of an innovative drug — human immunoglobulin containing antibodies against SARS-CoV-2.

A series of reports on completed clinical trials of bioequivalence of drugs was prepared in a short time.

The report of the phase III study of the Russian drug for the treatment of patients with COVID-19 was prepared and finalized in a short time.

This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of viral ...

CPD has prepared a protocol for a phase 3 study of a promising broad-spectrum drug used in the treatment of patients with coronavirus infection (COVID-19) of moderate and severe forms as part of standard therapy.

After the approval of the Ministry of Health of the Russian Federation, CPD will...

The recruitment of patients to phase III studies of a Russian drug for the treatment of patients with COVID-19 has been completed ahead of schedule.

This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of...